The most significant recent healthcare law in the United States is the Inflation Reduction Act (IRA), signed on August 16, 2022. It represents the largest set of changes to Medicare drug pricing in decades, including caps on out-of-pocket costs, a $35 monthly limit on insulin, and the first-ever authority for Medicare to negotiate prescription drug prices directly with manufacturers. Alongside it, the No Surprises Act (effective 2022) protects privately insured patients from unexpected medical bills. Together, these laws reshape how millions of Americans pay for healthcare.
The $2,000 Cap on Drug Costs
Before the Inflation Reduction Act, Medicare Part D had no hard ceiling on what beneficiaries could spend out of pocket on prescriptions. Someone taking expensive medications for cancer or autoimmune conditions could face costs of $10,000 or more per year. Starting in 2025, annual out-of-pocket spending on Part D prescriptions is capped at $2,000, period. Once you hit that number, your plan covers the rest for the remainder of the year.
This single change is projected to reduce out-of-pocket spending by about $7.4 billion annually across more than 18.7 million enrollees. That works out to roughly $400 per person among those who benefit. The cap also includes an option to spread your costs across the year in monthly installments rather than paying large sums upfront when you fill expensive prescriptions early in the year.
The $35 Insulin Cap
Insulin prices had become one of the most visible symbols of runaway drug costs in the U.S., with some patients rationing doses because they couldn’t afford refills. The IRA caps out-of-pocket costs for insulin at $35 per monthly prescription for Medicare enrollees. This took effect January 1, 2023, for Part D (pharmacy-filled prescriptions) and July 1, 2023, for Part B (insulin administered in a clinical setting, such as through insulin pumps).
The cap applies regardless of how much insulin you use or which brand you’re prescribed, as long as it’s a covered product under your plan. Several major insulin manufacturers have since voluntarily extended similar price limits to privately insured and uninsured patients, though those voluntary commitments aren’t required by law.
Medicare Can Now Negotiate Drug Prices
For the first time, Medicare has the legal authority to negotiate prices directly with pharmaceutical companies for certain high-cost drugs. Previously, Medicare was required to accept whatever price manufacturers set. The process started with 10 drugs selected for the first round of negotiations, which began in February 2024. The negotiated prices take effect in 2026, and additional drugs will be added in subsequent years.
The law also includes an inflation rebate provision that penalizes drug companies if they raise prices faster than the general rate of inflation. If a manufacturer increases the price of a Medicare-covered drug beyond the inflation rate, it must pay a rebate back to Medicare. Companies that fail to pay face civil monetary penalties. This applies to drugs covered under both Part B (administered by doctors) and Part D (filled at pharmacies).
Free Vaccines for Medicare Enrollees
Before the IRA, Medicare Part D enrollees often faced significant copays for recommended adult vaccines. A shingles vaccination, for example, could cost $200 or more out of pocket. As of January 1, 2023, the law eliminated all cost sharing and deductibles for adult vaccines recommended by federal health authorities and covered under Part D.
This includes vaccines for shingles, RSV, tetanus, diphtheria, pertussis (whooping cough), hepatitis A, hepatitis B, measles/mumps/rubella, and even vaccines recommended for international travel. The law also expanded access to adult vaccines under Medicaid and the Children’s Health Insurance Program (CHIP), closing gaps that had left some lower-income adults paying out of pocket for routine immunizations.
Limits on Premium Increases
A less publicized but important provision constrains how fast Part D premiums can rise. From 2024 through 2029, average premium increases are limited to roughly $2 per month. On top of that, no individual plan’s total Part D premium can jump by more than $35 from one year to the next. This prevents the scenario where a plan dramatically raises premiums in a single year, forcing enrollees to scramble for alternatives during open enrollment.
Extended Marketplace Subsidies
The IRA also extended the enhanced premium tax credits that lower monthly costs for people who buy health insurance through the Affordable Care Act marketplace (Healthcare.gov and state exchanges). These enhanced subsidies were originally introduced in 2021 and made coverage significantly cheaper for middle-income households that previously earned too much to qualify for substantial help. The current enhanced credits are set to expire at the end of 2025, and whether Congress extends them again will determine premiums for millions of marketplace enrollees heading into 2026.
Protection From Surprise Medical Bills
The No Surprises Act, which took effect in January 2022, addresses a different but equally frustrating problem: getting an unexpectedly large bill because a doctor, anesthesiologist, or other provider involved in your care turned out to be outside your insurance network. This happened most commonly in emergencies, when you had no ability to choose who treated you, and sometimes even during planned procedures at in-network hospitals where individual specialists weren’t covered.
The law bans surprise bills for most emergency services, even if the provider or facility is out of network and you didn’t get prior authorization. It also prohibits out-of-network charges for non-emergency services provided by out-of-network clinicians at in-network facilities, such as a radiologist or assistant surgeon you never selected. In these situations, you can only be charged your normal in-network cost sharing (copays and coinsurance). The provider and your insurer must work out the payment difference between themselves.
These protections apply to anyone with employer-sponsored insurance, marketplace plans, or individual health insurance purchased directly from an insurer. Air ambulance services from out-of-network providers are also covered under the law.
Changes to Medicare Advantage Oversight
New rules finalized for 2025 also tighten oversight of Medicare Advantage, the private insurance alternative to traditional Medicare that now covers more than half of all Medicare beneficiaries. One major change targets prior authorization, the process where your insurer must approve a treatment before you receive it. Plans are now required to analyze whether their prior authorization policies disproportionately affect underserved populations, including people with disabilities and those receiving low-income subsidies. The results of that analysis must be published on the plan’s website.
The rules also crack down on aggressive marketing practices. Agents and brokers now receive a fixed compensation amount regardless of which plan they enroll someone in, removing the financial incentive to steer people toward plans that pay higher commissions rather than plans that best fit their needs. Third-party marketing organizations can no longer share your personal information with other marketers without your explicit, individual written consent for each organization that would receive your data.